This is a working overview of Preclinical research, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-11. Anything still debated is marked as such rather than presented as settled.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
== Personal life, illness and death == On 7 July 1967, Olofsson became engaged to Madiorie Britmer in prison. He married Marijke Demuynck from Belgium in 1976; they occasionally lived in a large house in the Belgian countryside. The marriage with Marijke ended in 1999. He was the father of six children: the youngest son with his fiancée, three older sons with Marijke and two daughters from before his marriage. Olofsson died in Arvika, Sweden, on 24 June 2025, aged 78, following a long period of ill health.
Morpholino nucleic acids replace the sugar with a morpholine component, and the phosphate with a phosphorodiamidate component. Miravirsen is an antisense drug candidate that incorporates both locked nucleic acid sugar components and phosphorothioate groups.
==== Cough ==== Codeine was once viewed as the "gold standard" in cough suppressants, but this position has since been questioned. Some recent placebo-controlled trials have found that it may be no better than a placebo for some causes including acute cough in children. As a consequence, it is not recommended for children. Additionally, there is no evidence that hydrocodone is useful in children. Similarly, a 2012 Dutch guideline regarding the treatment of acute cough does not recommend its use. Low dose morphine may help chronic cough but its use is limited by side effects.
== Immobilization == See Immobilized enzyme for more information. There are several reasons for immobilizing an enzyme. In addition to more convenient handling of the enzyme, it provides for its facile separation from the product, thereby minimizing or eliminating protein contamination of the product. Immobilization also facilitates the efficient recovery and re-use of costly enzymes, in many applications a conditio sine qua non for economic viability, and enables their use in continuous, fixed-bed operation. A further benefit is often enhanced stability, under both storage and operational conditions, e.g. towards denaturation by heat or organic solvents or by autolysis. Enzymes are rather delicate molecules that can easily lose their unique three-dimensional structure, essential for their activity, by denaturation (unfolding). Improved enzyme performance via enhanced stability, over a broad pH and temperature range as well as tolerance towards organic solvents, coupled with repeated re-use is reflected in higher catalyst productivities (kg product/kg enzyme) which, in turn, determine the enzyme costs per kg product. Basically, three traditional methods of enzyme immobilization can be distinguished: binding to a support(carrier), entrapment (encapsulation) and cross-linking. Support binding can be physical, ionic, or covalent in nature. However, physical bonding is generally too weak to keep the enzyme fixed to the carrier under industrial conditions of high reactant and product concentrations and high ionic strength.
Proponents of wheatgrass make many claims for its health properties, ranging from promotion of general well-being to cancer prevention. However, according to the American Cancer Society, "available scientific evidence does not support the idea that wheatgrass or the wheatgrass diet can cure or prevent disease". Several trials and clinical reports report benefits in specific conditions e.g., reduced transfusion needs in thalassemia, reduced some chemotherapy side effects, improvements in some inflammatory bowel disease metrics, or modest antioxidant marker changes. However, the trials are generally small, often short. Top reviews advise cautious interpretation and call for larger, better-designed trials.
Sources: en.wikipedia.org
=== Pregnancy === Before 2015, tazarotene was considered a Category X drug (meaning its use was contraindicated during pregnancy) according to US Food and Drug Administration (FDA) guidelines, despite demonstrating similar plasma retinoid levels as adapalene and tretinoin, which were classified as Category C drugs. Under the FDA's updated Pregnancy and Lactation Labeling Rule which eliminated the lettered pregnancy categories and came into effect in 2015, tazarotene was determined to be contraindicated in pregnancy. Because of the lack of pregnancy outcomes data for the drug, the determination was based on the teratogenic effects observed in rat and rabbit studies.
== Etymology == The word Portugal derives from Latin Portus Cale, a Roman name meaning 'port of Cale', itself the origin of the name of the Portuguese city of Porto, while Cale was a town on the Douro. There is no consensus on the etymology of Cale. It could derive from the pre-Indo-European word Kala, meaning 'shelter' or 'refuge', passed into the Celtic language in the form Cale, with the meaning of 'land' or 'mountain'. The ethnonym Calaico/a then came from the Gallaeci, Celtic peoples of northwestern Iberia, and came to mean 'one of the land' or 'one of the place. During the Middle Ages, the region around Portus Cale became known by the Visigoths as Portucale and by the Suebi as Parochiale. The name Portucale evolved into Portugale; by the 11th and 12th centuries Portugal referred to the region between the Douro and Minho rivers.
The Gallery of Mineralogy, looking across the formal garden and close to the Gallery of Evolution, was constructed between 1833 and 1837 by Charles Rohault de Fleury in a neoclassical style, with two porticos of Doric columns. Directly in front is the rose garden, renewed in 1990 with 170 types of European roses, as well as a Japanese pagoda tree (Styphnolobium japonicum), planted there by Bernard de Jussieu in 1747. The gallery contains over 600,000 stones and fossils. It is particularly known for its collection of giant crystals, including colourful examples of azurite, tourmaline (rubelite), malachite and ammonite.ammonite Other displays include the jars and vestiges of the original royal apothecary of Louis XIV, and three Florentine marble marquetry tables from the palace of Cardinal Mazarin. The gallery also contains a large collection of meteorites which have been gathered from around the world. This includes a large fragment of Canyon Diablo meteorite, a piece of an asteroid which landed on Earth about 550,000 years ago and created the Meteor Crater in Arizona. It weighs 360 kg (790 lb).
In early 2021 Bolsonaro's approval ratings fell again, mostly due to the government's response to the COVID-19 pandemic, vaccination controversies, and the concurrent economic crisis that evolved under his watch. Days after Brazil surpassed Russia as the country worst hit by COVID, Bolsonaro held a political rally in Brasília; his supporters and his own security guards wore masks, but he did not. In June 2021, nationwide protests erupted against Bolsonaro's response to the pandemic; in São Paulo alone there were estimated to be 100,000 protesters on the streets. In July, YouTube removed videos posted by Bolsonaro for spreading false information about the virus. YouTube has reportedly removed 15 videos altogether; one that was removed had shown Brazil's former health minister, Eduardo Pazuello, comparing the virus to HIV. In other videos, Bolsonaro criticized efforts to stop the spread of the virus, such as wearing masks or taking the vaccine. By the end of June 2021, more members of the opposition started to call for his impeachment over his handling of the pandemic and spreading misinformation. The opposition signed a document with multiple accusations, such as blaming Bolsonaro for the deaths of 500,000 Brazilians from COVID-19, stating that his government had blatantly turned down expert advice on tackling the virus, and at least 20 other grievances. In July 2021, Bolsonaro claimed on Brazilian radio that his government's greatest achievement was "two and a half years without corruption". In the same month, a scandal dubbed "vaccine-gate" emerged.
Sources: en.wikipedia.org
== Mechanism of action == Troglitazone, like the other thiazolidinediones (pioglitazone and rosiglitazone), works by activating peroxisome proliferator-activated receptors (PPARs). Troglitazone is a ligand to both PPARα and – more strongly – PPARγ. Troglitazone also contains an α-Tocopherol moiety, potentially giving it vitamin E-like activity in addition to its PPAR activation. It has been shown to reduce inflammation. Troglitazone use was associated with a decrease of nuclear factor kappa-B (NF-κB) and a concomitant increase in its inhibitor (IκB). NFκB is an important cellular transcription regulator for the immune response.
H2SO4 + CH3CO2Na → NaHSO4 + CH3COOH Similarly, treating potassium nitrate with sulfuric acid produces nitric acid. Sulfuric acid reacts with sodium chloride, and gives hydrogen chloride gas and sodium bisulfate:
===== MeSH D08.811.682.732 – peroxidases ===== MeSH D08.811.682.732.332 – catalase MeSH D08.811.682.732.360 – chloride peroxidase MeSH D08.811.682.732.380 – cytochrome-c peroxidase MeSH D08.811.682.732.440 – eosinophil peroxidase MeSH D08.811.682.732.500 – glutathione peroxidase MeSH D08.811.682.732.512 – horseradish peroxidase MeSH D08.811.682.732.512.900 – wheat germ agglutinin-horseradish peroxidase conjugate MeSH D08.811.682.732.525 – iodide peroxidase MeSH D08.811.682.732.550 – lactoperoxidase MeSH D08.811.682.732.700 – peroxidase
Milos Vratislav Novotny (born 19 April 1942) is an American chemist, currently the Distinguished Professor Emeritus and Director of the Novotny Glycoscience Laboratory and the Institute for Pheromone Research at Indiana University, and also a published author. Milos Novotny received his Bachelor of Science from the University of Brno, Czechoslovakia in 1962. In 1965, Novotny received his Ph.D. at the University of Brno. Novotny also holds honorary doctorates from Uppsala University, Masaryk University and Charles University, and he has been a major figure in analytical separation methods. Novotny was recognized for the development of PAGE Polyacrylamide Gel-filled Capillaries for Capillary Electrophoresis in 1993. In his years of work dedicated to analytical chemistry he has earned a reputation for being especially innovative in the field and has contributed a great deal to several analytical separation methods. Most notably, Milos has worked a great deal with microcolumn separation techniques of liquid chromatography, supercritical fluid chromatography, and capillary electrophoresis. Additionally, he is known for his research in proteomics and glycoanalysis and for identifying the first mammalian pheromones.
== Bibliography == McNeill, A; Brose, LS; Calder, R; Bauld, L; Robson, D (February 2018). "Evidence review of e-cigarettes and heated tobacco products 2018" (PDF). UK: Public Health England. pp. 1–243. Stratton, Kathleen; Kwan, Leslie Y.; Eaton, David L. (January 2018). Stratton, Kathleen; Kwan, Leslie Y.; Eaton, David L. (eds.). Public Health Consequences of E-Cigarettes (PDF). National Academies of Sciences, Engineering, and Medicine (National Academies Press). pp. 1–774. Bibcode:2018nap..book24952N. doi:10.17226/24952. ISBN 978-0-309-46834-3. PMID 29894118. McNeill, A; Brose, LS; Calder, R; Hitchman, SC; Hajek, P; McRobbie, H (August 2015). "E-cigarettes: an evidence update" (PDF). UK: Public Health England. pp. 1–113. "Electronic Nicotine Delivery Systems and Electronic Non-Nicotine Delivery Systems (ENDS/ENNDS)" (PDF). World Health Organization WHO. August 2016. pp. 1–11. Wilder, Natalie; Daley, Claire; Sugarman, Jane; Partridge, James (April 2016). "Nicotine without smoke: Tobacco harm reduction". UK: Royal College of Physicians. pp. 1–191. "State Health Officer's Report on E-Cigarettes: A Community Health Threat" (PDF). California Tobacco Control Program. California Department of Public Health. January 2015. pp. 1–21. This article incorporates text from this source, which is in the public domain.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.